Alkermes Advances in Narcolepsy Treatment Race with Positive Phase 2 Results
Alkermes, a prominent player in the pharmaceutical industry, has reported encouraging results from its phase 2 clinical trial for narcolepsy type 1 (NT1), intensifying competition with Takeda in the pursuit of a potential blockbuster treatment.The midphase Vibrance-1 study, which involved 92 adult participants with NT1, demonstrated statistically significant improvements in wakefulness across all three tested doses of Alkermes' drug candidate, alixorexton. Patients achieved "normative wakefulness," with sleep latency extending beyond 20 minutes, meeting the trial's primary endpoint.
